<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178969</url>
  </required_header>
  <id_info>
    <org_study_id>SHP-608-002</org_study_id>
    <nct_id>NCT02178969</nct_id>
  </id_info>
  <brief_title>Short Term Observational Study in DEB Patients</brief_title>
  <official_title>A Prospective Short-term Study to Evaluate Methodologies for the Assessment of Disease Extent, Impact, and Wound Evolution in Patients With Dystrophic Epidermolysis Bullosa (DEB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand disease extent and to identify appropriate
      methodologies to evaluate (dystrophic epidermolysis bullosa) DEB in a quantitative and
      qualitative manner.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Surface Area (WSA) of patient- and investigator-selected wounds</measure>
    <time_frame>Over 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Surface Area (WSA) as a percentage of Body Surface Area (BSA) in patients with DEB</measure>
    <time_frame>Over 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number, severity and relationship to study procedures of adverse events (AEs) and serious AEs (SAEs)</measure>
    <time_frame>Over 4 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">29</enrollment>
  <condition>Dystrophic Epidermolysis Bullosa</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Optional genetic test for DEB diagnosis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with DEB.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent is provided. Patients 18 years of age and older, and
             parent(s)/legal guardian(s) of patients younger than 18 years of age, must provide
             written informed consent prior to participating in the study; additionally, informed
             assent will be obtained from patients younger than 18 years of age as specified by
             local requirements.

          2. Patient must have a documented diagnosis of DEB based on genetic analysis showing a
             mutation in COL7A1 or, in the opinion of the investigator, a confirmed diagnosis of
             DEB based on histologic criteria (antigen mapping or electron microscopy).

          3. Patient must have at least 5 wounds that are suitable for imaging, in the opinion of
             the investigator, at the time of enrollment.

          4. Patient is willing and able to undergo the protocol-specified procedures.

        Exclusion Criteria:

          1. Patient has used or is currently using experimental treatment for DEB including, but
             not limited to, bone marrow transplantation, systemic immune suppression, or
             experimental procedures that involve live cells, with potential for systemic spread
             such as gene transfer, stem cell infusions, or other cell type injections such that,
             in the opinion of the investigator, inclusion poses an unacceptable risk to the
             patient or interpretation of these study data.

          2. Patient has squamous cell carcinoma with evidence of locally invasive disease or
             distant metastases.

          3. Patient is pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Wijatyk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Childrens Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Specialists Pty Ltd</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salzburger Landeskliniken</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno</name>
      <address>
        <city>Brno</city>
        <zip>613 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Génétique et INSERM UMR 1163, Laboratoire de Génétique des maladies cutanées - Institut Imagine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico Dell'immacolata IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2014</study_first_posted>
  <last_update_submitted>May 28, 2015</last_update_submitted>
  <last_update_submitted_qc>May 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

